Pharmacovigilance Analysis on Cerebrovascular Accidents and Coronavirus disease 2019 Vaccines
Aggarwal, P.
Show abstract
IntroductionRecently, there have been reports of cerebrovascular accidents (CVA) occurring in individuals who have received the Coronavirus disease 2019 (COVID-19) vaccine. ObjectiveThe objective of this analysis was to determine if a statistically significant signal exists in post-marketing safety reports between CVA and the three COVID-19 vaccines being administered in the United States of America (Pfizer, Moderna, Janssen). MethodsA pharmacovigilance disproportionality analysis on adverse events reported with COVID-19 vaccines was conducted using data from Vaccine Adverse Event Reporting System. ResultsA statistically significant signal was found between CVA events and each of the three COVID-19 vaccines (Pfizer/BioNTechs, Modernas and Janssens) in the VAERS database. Females and individuals of age 65 or older had higher number of case reports of CVA events with the COVID-19 vaccines. Females had also more COVID-19 adverse event reports in which a CVA was reported and resulted in the patient having permanent disability or death. LimitationsRandomized controlled trials are needed to further analyze this signal. ConclusionPatients should be made aware of the risk-benefit and symptoms to watch out for that may indicate the onset of a CVA and informed to seek medical care as soon as possible if they develop these symptoms.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database 97%
- Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine reported to EudraVigilance database 94%
- Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine 92%
Similar papers in this journal
- Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval 92%
- Intradermal versus Intramuscular Administration of Influenza Vaccination: Rapid Review and Meta-analysis 91%
- Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort Study 90%
Similar papers in this journal
- Evaluation of Febrile Seizure Risk Following Ancestral Monovalent COVID-19 mRNA Vaccination Among U.S. Children Aged 2-5 Years 93%
- Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S. 93%
- A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and Myocarditis using Five European Databases 92%
Similar papers in this journal
- Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study 95%
- Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course 92%
- Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort 91%
Similar papers in this journal
- Covid-19 Vaccination in Pregnancy: A Systematic Review 93%
- Good recovery of immunization stress-related responses presenting as cluster of stroke-like events following CoronaVac and ChAdOx1 vaccinations 93%
- Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.